Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

• Published in: Diabetes care Vol. 41; no. 2; pp. 258 - 266
• Main Authors: Ahmann, Andrew J., Capehorn, Matthew, Charpentier, Guillaume, Dotta, Francesco, Henkel, Elena, Lingvay, Ildiko, Holst, Anders G., Annett, Miriam P., Aroda, Vanita R.
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01.02.2018
• Subjects: Adult; Aged; Aged, 80 and over; Antidiabetics; Blood Glucose - drug effects; Blood Glucose - metabolism; Body weight; Body Weight - drug effects; Clinical trials; Delayed-Action Preparations - administration & dosage; Delayed-Action Preparations - adverse effects; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Drug Administration Schedule; Drug therapy; Drugs; Evidence-based medicine; Exenatide; Female; Glucagon-Like Peptides - administration & dosage; Glucagon-Like Peptides - adverse effects; Glucose monitoring; Glycated Hemoglobin A - drug effects; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Male; Metformin - administration & dosage; Middle Aged; Peptides - administration & dosage; Peptides - adverse effects; Research design; Safety; Treatment Outcome; Venoms - administration & dosage; Venoms - adverse effects; Weight reduction; Young Adult

To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes. In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs wer...